scholarly journals Is secretory breast carcinoma underdiagnosed? In the era of targeted therapy should there be a low threshold to screen for NTRK immunohistochemistry in triple negative breast cancers?

Pathology ◽  
2019 ◽  
Vol 51 (6) ◽  
pp. 653-655 ◽  
Author(s):  
Matthew Zaborowski ◽  
Anthony J. Gill
Keyword(s):  
Targeted Therapy ◽  
Breast Carcinoma ◽  
Triple Negative ◽  
Breast Cancers ◽  
Low Threshold ◽  
Secretory Breast Carcinoma

scholarly journals Successful Targeted Therapy of Refractory Pediatric ETV6-NTRK3 Fusion-Positive Secretory Breast Carcinoma

2017 ◽  
pp. 1-8 ◽  
Author(s):  
Neerav Shukla ◽  
Stephen S. Roberts ◽  
Mollah O. Baki ◽  
Qazi Mushtaq ◽  
Paul E. Goss ◽  
...  
Keyword(s):  
Targeted Therapy ◽  
Breast Carcinoma ◽  
Secretory Breast Carcinoma

scholarly journals A OBSERVATIONAL STUDY ON CYTOKERATIN 5/6 EXPRESSION IN BREAST CARCINOMA PATIENTS AND CORRELATED WITH HORMONAL STATUS.

2020 ◽  
pp. 63-65
Author(s):  
Rubaiya Ahmad ◽  
Syed Meraj Imam ◽  
Debarshi Jana
Keyword(s):  
Breast Carcinoma ◽  
Research Study ◽  
Triple Negative ◽  
High Grade ◽  
Breast Cancers ◽  
Genetic Characteristics ◽  
Triple Negative Breast Carcinoma ◽  
Cytokeratin 5 ◽  
Malignant Lesions ◽  
Diagnostic Modalities

INTRODUCTION Breast cancer is the second most common cause of morbidity and mortality worldwide in women. They vary remarkably in terms of clinical presentation, history, behaviour and genetic characteristics. There has been a significant increase in overall incidence of breast cancers especially so in the developing countries attributable mainly to globalization causing adaptation of western life style and improved access to diagnostic modalities. OBJECTIVE OF THE RESEARCH Study of cytokeratin 5/6 expression in proliferative, preinvasive and malignant lesions of breast. ER/PR expression in proliferative, preinvasive and malignant lesions of breast. Correlation of data using appropriate statistical methods. METHODOLOGY Patients attending the Dept of Pathology, Sri Krishna Medical Collage Muzaffarpur, Bihar with epithelial breast tumor. RESULT AND CONCLUSION We found that cytokeratin 5/6 expression in Breast Carcinoma was significantly associated with high grade of the tumour. cytokeratin 5/6 expression was significantly associated with advanced stage of the tumour. It was found that cytokeratin 5/6 expression was significantly correlated with ki67 in Breast Carcinoma patients. Hormonal receptor like ER and PR were was significantly associated with cytokeratin 5/6 expression tumour. Triple negative Breast Carcinoma patient was significantly associated with high grade of cytokeratin 5/6 expression tumour.

scholarly journals NTRK, RET, ROS1, and ALK Gene Fusion in HER2 Immunohistochemistry 2+ Breast Carcinoma

2021 ◽  
Author(s):  
Shafei Wu ◽  
Xiaohua Shi ◽  
Kaimi Li ◽  
Ying Jiang ◽  
Yuanyuan Liu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Clinical Practice ◽  
Targeted Therapy ◽  
Breast Carcinoma ◽  
Cancer Patients ◽  
Triple Negative ◽  
Fusion Rate ◽  
Fusion Genes ◽  
Breast Cancer Patients ◽  
Cell Lung Carcinoma

Abstract ObjectiveHER2 immunohistochemistry (IHC) 2+ breast cancer patients need to determine the final HER2 status by fluorescence in situ hybridization (FISH) for selection of suitable treatment options. Although the HER2-positive cases can benefit from the anti-HER2 targeted therapy, it only made a small proportion of this group, so finding more targeted therapy methods is necessary. NTRK, RET, ROS1 and RET gene fusions have been fully investigated in non-small cell lung carcinoma and are subject to targeted therapy in clinical practice and trials. However, there are only few reports investigating these four fusion genes in breast cancer. Our study is designed to evaluate the four fusion genes in HER2 IHC 2+ breast cancer patients to find an alternative treatment option. MethodsOne hundred and seventy-seven tissue samples were included. IHC was employed to assess ALK and NTRK protein levels. FISH probes specific for HER2, ALK, NTRK1, NTRK2, NTRK3, ROS1 and RET were used. ResultsThe HER2-positivity rate of all HER2 IHC 2+ cases were 5.7%. The total fusion rate of the four oncogenes was 3.95% in HER2 IHC 2+ breast cancer patients. The fusion-positive patients were prone to be ER/PR/HER2 IHC triple negative (P=0.01) and were associated with poorly differentiated tumor (P=0.005). The NTRK, RET, ROS1, and ALK fusion rate was 0.56%, 1.13%, 1.13%, 1.13%, respectively. ConclusionsNRTK, RET, ROS1, and ALK fusion rearrangements were detected in triple-negative breast carcinoma patients which can provide patients with alternate treatment opportunities in clinical practice.

Characterisation of GATA3 expression in invasive breast cancer: differences in histological subtypes and immunohistochemically defined molecular subtypes

2017 ◽  
Vol 70 (11) ◽  
pp. 926-934 ◽  
Author(s):  
Tang Shaoxian ◽  
Yu Baohua ◽  
Xu Xiaoli ◽  
Cheng Yufan ◽  
Tu Xiaoyu ◽  
...  
Keyword(s):  
Breast Carcinoma ◽  
Triple Negative ◽  
Metastatic Breast ◽  
Her2 Overexpression ◽  
Specific Marker ◽  
Breast Cancers ◽  
Breast Carcinomas ◽  
Histological Subtypes ◽  
Intrinsic Subtypes ◽  
Gata3 Expression

AimsGATA-binding protein 3 (GATA3) is a sensitive and relatively specific marker in breast and urothelial carcinomas. Its diagnostic utility in primary and metastatic breast cancers has been explored and confirmed. However, the relationship between GATA3 expression and different breast carcinoma intrinsic subtypes has not been specifically defined in the literature despite a few reports with a small number of cases. The aim of the current investigation is to clarify GATA3 expression among different histological subtypes and surrogate molecular breast carcinoma subtypes in a large series of cases.MethodsImmunohistochemical staining of GATA3, GCDFP15 and mammaglobin was performed in a cohort of 1637 cases of primary invasive breast carcinoma. The association of GATA3 expression with different histological and surrogate intrinsic subtypes was assessed and compared with the expression of GCDFP15 and mammaglobin.ResultsThe overall positivity of GATA3 across the various immunohistochemistry-based surrogate intrinsic subtypes was 99.51% for luminal A-like, 97.70% for luminal B-like, 68.50% for HER2 overexpression and 20.16% for triple negative breast cancers. GATA3 expression was positively correlated with estrogen receptor (ER)-positive (luminal subtypes) breast carcinomas. For luminal-like and HER2 overexpression subtypes, GATA3 was much more sensitive than GCDFP15 and mammaglobin. For triple negative tumours, GATA3 was less sensitive than GCDFP15.ConclusionsGATA3 exhibits a relatively high sensitivity for breast carcinomas. It is more sensitive than GCDFP15 and mammaglobin in luminal-like and HER2 overexpression subtypes. GATA3 expression is associated with breast carcinomas of luminal subtype and low histological grade.

scholarly journals A Clinicopathological Study of Breast Carcinoma- Comparison of Triple Negative with Non-Triple Negative Breast Cancers

2020 ◽  
Vol 05 (02) ◽  
pp. 56-62
Author(s):  
Khandekar Prachi ◽  
Vimal Shruti ◽  
Gore Charusheela ◽  
Jain Kanika ◽  
Dharwadker Arpana ◽  
...  
Keyword(s):  
Breast Carcinoma ◽  
Triple Negative ◽  
Breast Cancers ◽  
Clinicopathological Study

Abstract 15: Imputing a more targeted therapy for triple-negative breast cancers

2020 ◽  
Author(s):  
Robert F. Gruener ◽  
Geoffrey L. Greene ◽  
R. Stephanie Huang
Keyword(s):  
Targeted Therapy ◽  
Triple Negative ◽  
Breast Cancers
Sign in / Sign up

Export Citation Format

Share Document